Novartis (NVS) stock slips as the company's anti-inflammatory agent Cosentyx fails primary goal in a Phase 3 trial for giant ...

A novel chimeric antigen receptor T-cell therapy may benefit patients with B-cell lymphomas who previously relapsed following ...